Kyverna Reports One-Year Follow-Up Data for CD19 CAR-T Therapy miv-cel in Stiff-Person Syndrome

On October 21, 2026, Kyverna reported one-year follow-up data from KYSA-8, a registrational Phase 2 trial of miv-cel (KYV-101) in stiff-person syndrome (SPS). In 26 patients with inadequate response to prior immunotherapy, median improvement on the timed 25-foot walk test rose from 46% at week 16 to 49% (p<0.0001), and 95% of patients who achieved clinically meaningful improvement at week 16 maintained benefit at one year.